FDA Grants Special Access to Experimental Obesity Drug for One Person
FDA 特別允許一人使用實驗性肥胖藥物
Introduction
The Food and Drug Administration (FDA) and Eli Lilly have allowed one person to use retatrutide, an experimental weight-loss drug, through a special process known as 'compassionate use'.
美國食品藥物管理局 (FDA) 與禮來公司 (Eli Lilly) 允許一名人士透過一項稱為「同情使用」(compassionate use) 的特殊程序，使用一種名為 retatrutide 的實驗性減肥藥。
Main Body
Retatrutide is a new type of medication that targets three different receptors to help reduce weight. In a Phase 3 clinical trial, non-diabetic patients with obesity lost 28 percent of their body weight over 80 weeks, which is a result similar to what is achieved through weight-loss surgery. Usually, the FDA's 'compassionate use' program is only for patients with life-threatening illnesses who have no other treatment options and cannot join a clinical trial.
Retatrutide 是一種新型藥物，透過針對三種不同的受體來幫助減重。在一次第三期臨床試驗中，患有肥胖症但非糖尿病的患者在 80 週內減輕了 28% 的體重，結果與減重手術所達到的效果相似。通常，FDA 的「同情使用」計畫僅適用於患有危及生命疾病、沒有其他治療選擇且無法參加臨床試驗的患者。
In April, a senior doctor from the National Institutes of Health (NIH) requested the drug for a 79-year-old patient. This patient suffered from severe obesity, high blood pressure in the lungs, and sleep apnea. Because of the patient's age and other health problems, surgery was not an option, and a previous weight-loss drug had only worked moderately well.
四月，美國國家衛生研究院 (NIH) 的一名資深醫生為一名 79 歲的患者申請了該藥物。該患者患有嚴重肥胖、肺高壓症和睡眠呼吸暫停症。由於患者年齡較大且有其他健康問題，手術並非可行方案，且先前使用的減重藥物效果僅一般。
However, some experts have raised concerns about how this was handled. Richard Klein, who helped create the expanded access program, emphasized that the public notice was missing standard details, making it very hard to find. Furthermore, medical experts asserted that giving this access to just one person for common health conditions is very unusual. When asked if the patient is President Donald Trump, the White House and the Department of Health and Human Services (HHS) did not give a clear answer, stating only that the FDA reviews each case individually.
然而，部分專家對此處理方式提出擔憂。協助建立擴大獲取計畫的 Richard Klein 強調，公開通知中缺少標準細節，導致極難搜尋。此外，醫學專家主張，針對常見健康狀況而僅允許一人使用，是非常罕見的。當被問及患者是否為總統川普時，白宮與衛生及公共服務部 (HHS) 並未給出明確答覆，僅表示 FDA 會對每個個案進行個別審查。
Conclusion
This case is a very rare example of a single person receiving an experimental drug, and the identity of the patient has not been officially confirmed.
此案例是一個非常罕見的例子，即僅有一名人士獲得使用實驗性藥物的許可，且患者的身份尚未正式確認。
Vocabulary Learning
The 'Precision Shift': From Simple to Sophisticated
To move from A2 to B2, you must stop using generic words like good, bad, or big and start using Precise Modifiers. In this text, we see a perfect example of how to describe 'degree' and 'quality' without sounding like a beginner.
⚡ The Upgrade Path
Look at how the text describes the patient's situation. Instead of saying "The patient was very sick," it uses specific combinations:
- Severe obesity (Not just 'very fat', but a clinical level of seriousness).
- Moderately well (Not just 'okay', but a measured, medium level of success).
- Very rare (Not just 'not common', but emphasizing an extreme exception).
🛠️ B2 Power Move: The 'Adverb + Adjective' Combo
At the A2 level, you likely say: "The drug is new." At the B2 level, you describe the nature of that newness:
*"...an experimental weight-loss drug..."
Why this matters: "Experimental" tells us the drug is new, but it also tells us it is being tested and might be risky. That is the difference between basic communication and B2 fluency.
🔍 Spotting the 'Professional Tone'
Notice the word "asserted."
- A2: "Experts said that..."
- B2: "Medical experts asserted that..."
Using asserted instead of said transforms the sentence from a simple conversation into a formal argument. It suggests confidence and authority.
Quick Tip for your transition: Next time you want to say something is "very [adjective]," challenge yourself to find a specific B2 word (like severe, significant, or exceptional) to replace it.